Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Pharmaceutical Industry M&A Activity Surges in First Half of 2025

The pharmaceutical industry witnessed a flurry of merger and acquisition (M&A) activity in the first half of 2025, with 32 deals recorded across the sector. Despite facing significant headwinds, including regulatory challenges and geopolitical uncertainties, companies demonstrated a renewed appetite for strategic transactions, particularly in the closing month of June.

NoahAI News7/1/2025

Amgen's Bemarituzumab Shows Promise in Phase III Gastric Cancer Trial

Amgen's investigational monoclonal antibody, bemarituzumab, has demonstrated significant improvement in overall survival when combined with chemotherapy for patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer, according to recent Phase III trial results. This development marks a potential breakthrough in targeted therapy for gastric cancer, a disease often diagnosed at advanced stages with limited treatment options.

NoahAI News7/1/2025

Supernus Acquires Sage Therapeutics, Triggering Mass Layoffs and Industry Shakeup

In a significant move that has sent ripples through the pharmaceutical industry, Supernus Pharmaceuticals has announced its acquisition of Sage Therapeutics for $561 million upfront, with potential for the deal to reach $795 million based on certain milestones. This acquisition comes on the heels of Sage's recent struggles and marks a dramatic shift in the company's trajectory.

NoahAI News7/1/2025

AbbVie Acquires Capstan Therapeutics for $2.1B, Expanding In Vivo CAR-T Portfolio

AbbVie has announced the acquisition of Capstan Therapeutics in a deal worth up to $2.1 billion, marking a significant move into the emerging field of in vivo CAR-T therapy. The all-cash buyout gives AbbVie access to Capstan's novel technology for treating B cell-mediated autoimmune diseases and adds to a growing trend of pharmaceutical mergers and acquisitions in the industry.

NoahAI News7/1/2025

BMS Continues Workforce Reduction in New Jersey as Part of Cost-Cutting Strategy

Bristol Myers Squibb (BMS) is pressing forward with its extensive cost-cutting measures, focusing on its operations in Lawrenceville, New Jersey. The pharmaceutical giant has announced another round of layoffs, adding to the significant workforce reductions implemented since early 2024.

NoahAI News7/1/2025

Alzheimer's Drug Market Surges as Big Pharma Bets on New Treatments

The pharmaceutical industry has witnessed a dramatic shift in focus towards Alzheimer's disease treatments, with deal values skyrocketing and major players making significant acquisitions. This renewed interest comes in the wake of groundbreaking approvals for monoclonal antibody therapies, marking a new era in the fight against this devastating neurodegenerative condition.

NoahAI News7/1/2025

INmune Bio's Alzheimer's Drug XPro Fails to Meet Primary Endpoint in Phase II Trial

INmune Bio's investigational TNF inhibitor XPro has failed to demonstrate significant cognitive benefits in a Phase II trial for early Alzheimer's disease (AD) patients with signs of inflammation. The announcement, which led to a sharp decline in the company's stock price, highlights the ongoing challenges in developing effective treatments for this devastating neurodegenerative disorder.

NoahAI News7/1/2025

Moderna's mRNA Flu Vaccine Outperforms Standard Shot in Phase III Trial

Moderna's mRNA-based seasonal influenza vaccine, mRNA-1010, has demonstrated superior efficacy compared to a currently licensed flu shot in a large-scale Phase III trial. The results, announced on June 30, 2025, mark a significant milestone for the company and pave the way for potential regulatory submissions and the development of combination vaccines.

NoahAI News7/1/2025

Moderna's mRNA Flu Vaccine Shows Promise in Large Phase 3 Trial

Moderna, the pharmaceutical company known for its COVID-19 vaccine, has announced positive results from a large Phase 3 trial of its seasonal influenza vaccine. The mRNA-based shot outperformed existing marketed vaccines, potentially paving the way for the first messenger RNA influenza vaccine in the United States.

NoahAI News7/1/2025

Duke Researchers Propose New Framework for Evaluating AI Scribes Amid Surge in Venture Capital Funding

In a significant development for the healthcare technology sector, researchers at Duke University have proposed a novel framework for evaluating artificial intelligence (AI) scribing tools. This comes at a time when venture capital is pouring into AI scribe companies, with several firms announcing substantial funding rounds in recent months.

NoahAI News7/1/2025

Best Buy Divests Current Health as Co-Founder Reacquires Company with Ambitious Growth Plans

Best Buy has divested Current Health, the care-at-home technology company it acquired in 2021 for nearly $400 million. Christopher McGhee, co-founder of Current Health, has reacquired the company and returned as CEO with plans to build it into the "world's largest healthcare organization."

NoahAI News7/1/2025

FDA Issues Complete Response Letter to Unicycive, Delaying Kidney Disease Treatment

Unicycive Therapeutics has encountered a setback in its efforts to bring a new hyperphosphatemia treatment to chronic kidney disease (CKD) patients on dialysis. The U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to the company, citing manufacturing issues at a third-party vendor.

NoahAI News7/1/2025

1 2 3 4...67 »